Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese

European Journal of Clinical Pharmacology

Volumn 70, Issue 9, 2014, Pages 1073-1078

  Sugimoto, Mitsushige ^a   Shirai, Naohito ^b   Nishino, Masafumi ^b   Kodaira, Chise ^a   Uotani, Takahiro ^a   Sahara, Shu ^a   Ichikawa, Hitomi ^a   Kagami, Takuma ^a   Sugimoto, Ken ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Center for Clinical Research Hamamatsu University School of Medicine ^*  (Japan)

Author keywords

CYP2C19; Intragastric pH; Proton pump inhibitor; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; RABEPRAZOLE; TAKEPRONE; UNCLASSIFIED DRUG; CYP2C19 PROTEIN, HUMAN; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; ASPIRIN INDUCED GASTRODUODENAL MUCOSAL INJURY; CONTROLLED STUDY; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GENOTYPE; HELICOBACTER PYLORI; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH; WILD TYPE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; GENETICS; PH; SECRETION (PROCESS); STOMACH ACID; YOUNG ADULT;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2C19; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITORS; RABEPRAZOLE; YOUNG ADULT;

EID: 84927172816     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1713-y     Document Type: Article

References (42)

1. Barer D, Ogilvie A, Henry D et al (1983) Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. N Engl J Med 308:1571-1575 (Pubitemid 13063425)
2. Bell NJ, Burget D, Howden CW et al (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59-67
3. Sugimoto M, Nishino M, Kodaira C et al (2011) Impact of acid inhibition on esophagealmucosal injury induced by low-dose aspirin. Digestion 85:9-17. doi:10.1159/000329295
4. Walsh JH, PetersonWL (1995) The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 333:984-991
5. Furuta T, Sagehashi Y, Shirai N et al (2005) Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol 3:564-573 (Pubitemid 40824749)
6. Furuta T, Shirai N, Watanabe F et al (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453-460 (Pubitemid 35178870)
7. SugimotoM, Furuta T, Shirai N et al (2007) Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 12:317-323 (Pubitemid 47196333)
8. Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 13(Suppl 3):27-36 (Pubitemid 29389409)
9. Horai Y, Kimura M, Furuie H et al (2001) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 15:793-803 (Pubitemid 32500425)
10. Shirai N, Furuta T, Moriyama Y et al (2001) Effects of CYP2C19 genotypic differences in themetabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937 (Pubitemid 34014349)
11. Shirai N, Furuta T, Xiao F et al (2002) Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther 16:837-846 (Pubitemid 34407534)
12. Sugimoto M, Furuta T, Shirai N et al (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 76: 290-301 (Pubitemid 39313119)
13. Chang M, Dahl ML, Tybring G et al (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363 (Pubitemid 26011441)
14. Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661-666 (Pubitemid 27025913)
15. Furuta T, Ohashi K, Kosuge K et al (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561 (Pubitemid 29237329)
16. Furuta T, Shirai N, Takashima M et al (2001) Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11:341-348 (Pubitemid 32537408)
17. Sugimoto M, Furuta T, Shirai N et al (2005) Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 77:302-311 (Pubitemid 40470386)
18. Hatlebakk JG, Katz PO, Castell DO (1999) Medical therapy. Management of the refractory patient. Gastroenterol Clin N Am 28: 847-860
19. Joh T, Miwa H, Higuchi K et al (2007) Validity of endoscopic classification of nonerosive reflux disease. J Gastroenterol 42:444-449 (Pubitemid 47050006)
20. Miwa H, Sasaki M, Furuta T et al (2007) Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 26:69-77 (Pubitemid 46889840)
21. Sugimoto M, Nishino M, Kodaira C et al (2011) Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 17:1858-1865. doi:10.3748/wjg.v17.i14.1858
22. Klinkenberg-Knol EC, Festen HP, Jansen JB et al (1994) Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 121:161-167 (Pubitemid 24225631)
23. Peghini PL, Katz PO, Bracy NA et al (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763-767 (Pubitemid 29063918)
24. Hatlebakk JG, Katz PO, Kuo B et al (1998) Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 12:1235-1240 (Pubitemid 28565964)
25. Katsube T, Adachi K, Kawamura A et al (2000) Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049-1056 (Pubitemid 30618166)
26. Nishino M, Sugimoto M, Kodaira C et al (2010) Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 55:1627-1636. doi:10.1007/s10620-009-0920-3, CDAI: 19672708
27. Kodaira C, Sugimoto M, Nishino M et al (2009) Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects. Eur J Clin Pharmacol 65:593-600. doi:10.1007/s00228-009-0625-8, CDAI: 19238367
28. Furuta T, Shirai N, Xiao F et al (2001) Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 70:484-492, CDAI: 11719736
29. Furuta T, Shirai N, KodairaMet al (2007) Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 81:521-528, CDAI: 17215846
30. Uotani T, Sugimoto M, Nishino M et al (2012) Ability of rabeprazole to prevent gastricmucosal damage fromclopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2012.04.016, CDAI: 22542748
31. Kurata S, Kanagawa T, Yamada K et al (2001) Fluorescent quenching-based quantitative detection of specific DNA/RNA using a BODIPY((R)) FL-labeled probe or primer. Nucleic Acids Res 29: E34, CDAI: 11239011
32. Torimura M, Kurata S, Yamada K et al (2001) Fluorescence-quenching phenomenon by photoinduced electron transfer between a fluorescent dye and a nucleotide base. Anal Sci Int J Jpn Soc Anal Chem 17:155-160, CDAI: 11993654
33. Furuta T, Soya Y, Sugimoto M et al (2013) Rapid automated genotyping of CYP2C19 and Helicobacter pylori 23S rRNA gene in gastric juice. J Gastroenterol Hepatol Res 2:506-512
34. De Morais SM,Wilkinson GR, Blaisdell J et al (1994) Identification of a new genetic defect responsible for the polymorphism of (S)- mephenytoin metabolism in Japanese. Mol Pharmacol 46:594-598, CDAI: 7969038
35. Adachi K, Fujishiro H, Katsube T et al (2001) Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 16:1191-1196, CDAI: 11903734
36. Yasuda S, Horai Y, Tomono Yet al (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 58:143-154, CDAI: 7648764
37. Kawamura M, Ohara S, Koike T et al (2003) The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 17:965-973, CDAI: 12656699
38. Kawamura M, Ohara S, Koike T et al (2007) Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 22: 222-226. doi:10.1111/j.1440-1746.2006.04419.x, CDAI: 17295875
39. Sim SC, Risinger C, Dahl ML et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113, CDAI: 16413245
40. Sugimoto K, Uno T, Yamazaki H et al (2008) Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 65:437-439. doi:10.1111/j.1365-2125.2007. 03057.x, CDAI: 2291245
41. Kinoshita Y, Hongo M (2012) Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol 107:522-530. doi:10.1038/ajg.2012.19, CDAI: 22433921
42. Sugimoto M, Shirai N, Nishino M et al (2012) Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther 36:627-634. doi:10.1111/apt.12014, CDAI: 22882464